Titan International, Inc. Shares Condolences on Loss of Board Member Gary Cowger
WEST CHICAGO, Ill., Feb. 22, 2023 /PRNewswire/ -- Titan International, Inc. (NYSE: TWI) today released the following statement from its Chairman, Morry Taylor, and its President and CEO, Paul Reitz.
On behalf of our entire organization and the Board of Directors, we wish to express our deepest condolences and sympathy on the death of one of our directors, Gary Cowger. Gary had a long and illustrious life and career and was a director at Titan since 2014. Gary served as a board member for a number of companies, and on the boards of many nonprofit organizations. He enjoyed a long-term career with General Motors from 1965 until his retirement in December 2009. Our thoughts and prayers go out to Gary's entire family, his friends and the many colleagues he impacted throughout his life.
About Titan: Titan International, Inc. (NYSE: TWI) is a leading global manufacturer of off-highway wheels, tires, assemblies, and undercarriage products. Headquartered in West Chicago, Illinois, the company globally produces a broad range of products to meet the specifications of original equipment manufacturers (OEMs) and aftermarket customers in the agricultural, earthmoving/construction, and consumer markets. For more information, visit www.titan-intl.com.
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company"). This action, captioned Hope v. agilon health, inc., et...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...
